What it is
NMN (nicotinamide mononucleotide) is an NAD+ precursor — a key intermediate in the NAD+ salvage pathway. NAD+ levels decline with age, and NMN supplementation is studied for restoring NAD+ pools, supporting mitochondrial function, sirtuin activation, and DNA-repair capacity. It is an oral precursor, not an injectable peptide — grouped here because it sits beside NAD+ and the mitochondrial peptide family (MOTS-c, SS-31, humanin) in anti-aging research stacks.
Evidence boundary
Human supplement trials exist (oral NMN); dose-response literature still maturing. Research use is limited to laboratory and education contexts.
Trial evidence
- Oral NMN in human trials shows NAD+ elevation with generally good tolerance at 300–600 mg/day; animal longevity and metabolic studies are extensive.
Preparation and measurement
Oral dosing — no reconstitution, no BAC, no syringe math.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Conservative start | 300 mg | Oral | Once daily | 2.1 g/week |
| Standard research | 600 mg | Oral | Once daily | 4.2 g/week |
| Higher end | 1000 mg | Oral | Once daily | 7 g/week |
Conservative start
- Dose
- 300 mg
- Draw / measure
- Oral
- Frequency
- Once daily
- Weekly total
- 2.1 g/week
Standard research
- Dose
- 600 mg
- Draw / measure
- Oral
- Frequency
- Once daily
- Weekly total
- 4.2 g/week
Higher end
- Dose
- 1000 mg
- Draw / measure
- Oral
- Frequency
- Once daily
- Weekly total
- 7 g/week
Weekly totals apply only during the active phase.
Titration rules
- Common range: 300–1000 mg daily by mouth; many protocols start at 300 mg and move to 600 mg after a few weeks.
- NMN and NR (nicotinamide riboside) are the two main NAD+ precursors; NMN sits one step closer to NAD+ in the salvage pathway.
- Take with food is common practice; split larger doses if GI tolerance is a concern.
- Combined with NAD+ injections, keep the total NAD+ load in mind — they are complementary routes but both raise the same pool.